Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect against the three major neurodegenerative protein aggregates.
Key findingReview of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect
What the researchers found
Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect against the three major neurodegenerative protein aggregates.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.
Neuroscience and biobehavioral reviews, 173, 106159
Citation
Au, Hezekiah C T; Lam, Pak Ho; Lim, Poh Khuen; McIntyre, Roger S. (2025). Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.. Neuroscience and biobehavioral reviews, 173, 106159. https://doi.org/10.1016/j.neubiorev.2025.106159